Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile

  • T. Wikberg
  • A. Vuorela
Article
Received:

Summary

The metabolites of two inhibitors of catechol O-methyltransferase, nitecapone [3-(3,4-dihydroxy-5-nitrobenzylidene)2,4-pentanedione] and entacapone [(E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide], excreted in urine and bile by rats and in urine by mice, were compared and quantified by using HPLC with radiochemical detection after administration of [14C]-labelled compounds. With the exception of 3-O-methylated nitecapone, no major metabolites were found in rat bile that were not found in rat urine. For both compounds the major biotransformations were the same in the mouse and the rat. However, a bisulfite adduct of nitecapone was found in rat urine only, and reduction of the C=C and C=O groups of the nitecapone side chain was more extensive in the mouse. After entacapone administration, the products of amide N-dealkylation were more abundant in rat urine than in mouse urine. Most of the dose was excreted in urine and bile as O-conjugates. Most abundant were the O-glucuronides, while smaller amounts of O-sulfates and O-methylated metabolites were found in both species. One non-glucuronide glycoside of entacapone was found in urine of both rats and mice.

Keywords

[14C]-Nitecapone [14C]-entacapone metabolites rat mouse 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Männistö P.T., Ulmanen I., Lundström K., et al. (1992): Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res., 39, 291–350.PubMedGoogle Scholar
  2. 2.
    Männistö P.T., Kaakkola S. (1990): Rafionale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol. Toxicol., 66, 317–323.CrossRefPubMedGoogle Scholar
  3. 3.
    Nutt J.G., Fellman J.H. (1984): Pharmacokinetics of levodopa. Clin. Neuropharmacol., 7, 35–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Kaakkola S., Gordin A., Järvinen M., et al. (1990): Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin. Neuropharmacol., 13, 436–447.CrossRefPubMedGoogle Scholar
  5. 5.
    Keränen T., Gordin A., Karlsson M., et al. (1991): Effect of the novel catechol-O-methyltransferase inhibitor OR-611 in healthy volunteers. Neurology, 41, 213.Google Scholar
  6. 6.
    Aho P., Lindén I-B., Nissinen E., Pohto P. (1988): Prevention of cysteamine-induced duodenal ulcers in rats by a COMT-inhibitor. Dig. Dis. Sci., 33, 897.CrossRefGoogle Scholar
  7. 7.
    Pohto P., Aho P., Lindén I-B. (1990): Prevention of gastric and duodenal ulcers in rat models by nitecapone. Eur. J. Pharmacol., 183, 314.CrossRefGoogle Scholar
  8. 8.
    Suzuki Y.J., Tsuchiya M., Safadi A., Kagan V.E., Packer L. (1992): Antioxidant properties of nitecapone (OR-462). Free Radic. Biol. Med., 13, 517–525.CrossRefPubMedGoogle Scholar
  9. 9.
    Taskinen J., Wikberg T., Ottoila P., et al. (1991): Identification of major metabolities of the catechol-O-methyltransferase-inhibitor nitecapone in human urine. Drug Metab. Dispos., 19, 178–183.PubMedGoogle Scholar
  10. 10.
    Wikberg T., Taskinen J. (1993): Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog. Drug Metab. Dispos., 21, 323–333.Google Scholar
  11. 11.
    Wikberg T., Vuorela A., Ottoila P., Taskinen J. (1993): Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos., 21, 81–92.PubMedGoogle Scholar
  12. 12.
    Karlsson C., Honkanen E. (1991): Synthesis of two14C-labelled catechol-O-methyltransferase inhibitors. J. Labelled Compd. Radiopharm., 29, 237–239.CrossRefGoogle Scholar
  13. 13.
    Bäckström R., Honkanen E., Pippuri A., et al. (1989): Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J. Med. Chem., 32, 841–846.CrossRefPubMedGoogle Scholar
  14. 14.
    Veltkamp A.C. (1990): Radiochromatography in pharmaceutical and biomedical analysis. J. Chromatogr., 531, 101–129.CrossRefPubMedGoogle Scholar
  15. 15.
    Hall L.R., Hanzlik R.P. (1991): N-Dealkylation of tertiary amides by cytochrome P-450. Xenobiotica, 21, 1127–1138.CrossRefPubMedGoogle Scholar
  16. 16.
    Gessner T., Hamada N. (1970): Identification of p-nitrophenyl glucoside as a urinary metabolite. J. Pharm. Sci., 59, 1528–1529.CrossRefPubMedGoogle Scholar
  17. 17.
    Borgulya J., da Prada M., Dingemanse J., Scherschlicht R., Schläppi B., Zürcher G. (1991): Ro 40-7592. Drugs Future, 16, 719–721.Google Scholar
  18. 18.
    Hirom P.C., Millburn P., Smith R.L. (1972): Some physiological factors influencing the concentration of drugs at body sites. J. Mond. Pharm., 15, 10–20.Google Scholar
  19. 19.
    Klaassen C.D., Eaton D.L., Cagen S.Z. (1981): Hepatobiliary disposition of xenobiotics. In: Bridges J.W., Chasseaud L.F., eds.: Progress in Drug Metabolism, vol. 6, New York, Wiley.Google Scholar
  20. 20.
    Kuipers F., Dijkstra T., Havinga R., Asselt W., Volk R. (1985) Acute effects of pentobarbital-anaesthesia on bile secretion. Biochem. Pharmacol., 34, 1731–1736.CrossRefPubMedGoogle Scholar
  21. 21.
    Cooper B., Eakins M., Slater T.F. (1976): The effect of various anaesthetic techniques on the flow rate, constituents and enzymic composition of rat bile. Biochem. Pharmacol., 25, 1711–1718.CrossRefPubMedGoogle Scholar
  22. 22.
    Wang S.X., Sutfin T.A., Regårdh C.G. (1992): The effect of felodipine on bile flow in pentobarbital anaesthetized rats and conscious rats receiving bile salt supplementation. Eur. J. Drug Metab. Pharmacokinet., 17, 263–268.PubMedGoogle Scholar
  23. 23.
    Ernster L., Orrenius S. (1965): Substrate-induced synthesis of the hydroxylating enzyme system of liver microsomes. Fed. Proc., 24, 1190–1199.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • T. Wikberg
    • 1
  • A. Vuorela
    • 1
  1. 1.Orion ResearchOrion-Farmos PharmaceuticalsEspooFinland

Personalised recommendations